Skip to main content

Table 2 Microbiology of patients with device-associated osteomyelitis treated with daptomycin in the CORE database

From: A retrospective study of outcomes of device-associated osteomyelitis treated with daptomycin

Pathogens, n (%)a No follow-up in CORE 2009 Evaluable population
PJI OHAO
(n = 32) (n = 27) (n = 21)
Staphylococcus aureus (MRSA) 9 (28.1) 6 (22.2) 7 (33.3)
Staphylococcus aureus (MSSA) 2 (6.3) 3 (11.1) 4 (19.0)
Other Staphylococcus aureus b 1 (3.1) 1 (3.7) 0 (0.0)
Coagulase-negative staphylococci 3 (9.4) 6 (22.2) 3 (14.3)
Enterococcus spp. 4 (12.5) 3 (11.1) 3 (14.3)
Vancomycin-resistant enterococci 1 (3.1) 1 (3.7) 2 (9.5)
Streptococcus spp. 0 (0.0) 0 (0.0) 1 (4.8)
Other 7 (21.9) 3 (11.1) 1 (4.8)
  1. CORE Cubicin® Outcomes Registry and Experience, MRSA methicillin-resistant S. aureus, MSSA methicillin-susceptible S. aureus, OHAO other hardware-associated osteomyelitis, PJI prosthetic joint infection
  2. aPatients may have had more than one pathogen
  3. bOther S. aureus includes methicillin susceptibility unknown